Conjugate based systems for controlled drug delivery
AssigneeSmartCells, Inc.
InventorsTodd C. Zion, Thomas M. Lancaster
Life of this patent
Estimating the term…
Abstract
Conjugates which comprise a drug and a ligand which includes a first saccharide; wherein the conjugate is characterized in that, when the conjugate is administered to a mammal, at least one pharmacokinetic or pharmacodynamic property of the conjugate is sensitive to serum concentration of a second saccharide. Exemplary conjugates and sustained release formulations are provided in addition to methods of use and preparation.
Claims46
A conjugate comprising a drug and a ligand including a first saccharide;
- wherein the conjugate is characterized in that, when the conjugate is administered to a mammal, at least one pharmacokinetic or pharmacodynamic property of the conjugate is sensitive to serum concentration of a second saccharide.
3-42. (canceled)
44-51. (canceled)
53-55. (canceled)
57-62. (canceled)
64-73. (canceled)
75-77. (canceled)
79-81. (canceled)
84-108. (canceled)
110-155. (canceled)
158-159. (canceled)
162-167. (canceled)
170-254. (canceled)
256-257. (canceled)
259-284. (canceled)
286-287. (canceled)
289-305. (canceled)
307-326. (canceled)
A conjugate comprising a formula selected from the group consisting of:
328-387. (canceled)
A conjugate comprising an insulin molecule conjugated to one or more ligands that are independently selected from the group consisting of aminoethylglucose (AEG), aminoethylmannose (AEM), aminoethylbimannose (AEBM), aminoethyltrimannose (AETM), 3-aminoethyl-N-acetylglucosamine (AEGA), and aminoethylfucose (AEF).
390-398. (canceled)
400-429. (canceled)
Dependencies are inferred from the claim text.